ARTICLES

USA TODAY - 04/20/2020

Marijuana’s big moment: Pot stores are now essential businesses. Will legal weed go mainstream?

Trevor Hughes

USA TODAY
Published: 6:09 a.m. ET Apr. 20, 2020 Updated: 9:46 a.m. ET Apr. 20, 2020
 

DENVER — The marijuana industry is embracing change.

Edible products and pre-rolled joints are out. Vape concentrates and loose “flower,” which can be packed into bongs or pipes or rolled into joints and provide more bang for the buck, are in. 

Stores are effectively closed. Instead, customers order online and pick up curbside, a major shift from when each buyer had to be personally verified by a licensed store worker. In California, stores have largely switched to an all-delivery model. 

The country’s burgeoning marijuana industry is working swiftly to adapt to its customers’ needs as the coronavirus outbreak wreaks havoc on the U.S. economy. With business owners unable to access federal bailouts because the drug remains illegally nationally and popular 4/20 events cancelled because of stay-at-home orders, sellers are pushing for new ways to reach customers and persuade lawmakers that legal weed has become a crucial industry for many Americans. 

Read more...

PRESS RELEASES

COVID-19 Press Release - 03/19/2020

COVID-19 Patients Should Avoid THC
Potential Harmful Side Effects of Cannabis on Infected Coronavirus Patients

March 18, 2020                                                                                                                                                                 

Missoula, MTAurelius Data, the first global patient perception big data company in plant-based medicines, cautions the public against the potential harmful side effects that can come from consuming cannabis products with Tetrahydrocannabinol (THC) if a patient is infected with COVID-19.

“We know that the epidemiology of COVID-19 is similar to the influenza virus and has a similar disease presentation. And we know that in studies[1] where THC was administered to mice with influenza, we saw an increase in viral loads and a decrease in the immune system to fight off the virus. It stands to reason that the same would hold true for Coronavirus and THC consumption could diminish the immune system of someone infected with the virus,” said Aurelius Data CEO Julie Armstrong.

More research is required to accurately map the relationship between the immune and endocannabinoid systems, but it’s well established that CBD helps to modulate autoimmune and inflammatory responses.

 “Although no clinical trials exist showing poorer outcomes in patients infected with COVID-19 who use therapeutic or recreational cannabis, the data from pre-human studies urge caution for these individuals in the face of the current viral epidemic,” notes Barry Mennen, MD. a clinician who utilizes medical cannabis in his primary care practice.

Aurelius Data has prepared a brief survey to better inform patients on how cannabis consumption affects viral infections. The questionnaire will ask a patient’s symptoms, if they are concerned about contracting COVID-19, what conditions they are currently treating with medical cannabis or other pharmaceuticals and what they feel is the effectiveness of the treatment.

The brief survey can be taken here: https://research.aureliusdata.com/COVID-19

“Medical Cannabis patients across this country are going to be affected by COVID-19 just like the rest of the population and they need to be aware of the interactions their cannabis medications could have on this disease. We are working to collect data in this under researched area and provide them with the best recommendations we can moving forward,” Armstrong added.

####

Aurelius Data, Inc is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution. Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user. 

Our anonymously gathered data follows HIPPA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the strain and create a reliable product use and efficacy reference for cannabis users.  Dr. Barry Mennen who is quoted, is also an adviser to Aurelius Data.

Contact: Gretchen Gailey, Media & PR Advisor, Aurelius Data MediaInquiries@aureliusdata.com, 202.489.3821

[1] https://www.karger.com/Article/Fulltext/481824

 

AD/ASA PArtnership - 06/11/2019

Americans for Safe Access and Aurelius Data Join Forces to Create a Research Platform to Benefit Cannabis Patients

 

WASHINGTON, June 11, 2019 (GLOBE NEWSWIRE) — Today, Aurelius Data, Inc.(AD), the premier patient perception big data company, and Americans for Safe Access (ASA), the leading advocacy organization dedicated to ensuring safe and legal access to cannabis (marijuana) for therapeutic use and research, announced a bold new partnership to gather and analyze millions of data points from cannabis patients. 

ASA and AD both recognize that while science has made significant strides in cannabis research, there is still a significant gap in education for providers and patients. With the partnership between ASA and AD, the data gathered and analyzed will advance the role of patient use and perception to the forefront of research. Combining that knowledge with chemical product analysis, patient perceived effectiveness, efficacy, form factor, and mechanisms of action (methods of administration) will yield a much-needed educational resource for patients and caregivers, providers, and the industry.

As stated by Dr. Amy Abernathy, the Acting CIO of the Federal Drug Administration, on May 31st of this year, “Systematic studies are needed. It sounds like a number of studies are available or underway. We also wonder if real-world evidence derived from electronic health records, personal monitors, administrative data, etc. can be used to address critical questions in this space.”

Through this joint patient-first initiative, ASA and AD seek to develop a research platform that creates a culture of transparency, integrity and education through data. Aurelius Data’s proprietary AURA platform and analysis tools will compile the use, perception and biometric data of consumers, for which conditions the products are being used and then matching that data with the product’s chemical analyses, and quality information. The insights generated from the platform will be available to users through the AURA mobile application, along with a community offering product education, support and best practices. #SafeAccess

“ASA is excited to be partnering with Aurelius Data, who shares a patient-first mission,” said Debbie Churgai, Interim Director of ASA. “Creating a patient focused community through the AURA platform gives our subscribers a way to connect and discover what regimens are working for other patients, offering an opportunity for real results and lasting change through research.” #MedicalCannabis, #CannabisAdvocacy

“We are so fortunate that ASA recognizes that this partnership allows us to be stronger together and to support a goal that is dear to all of us—to create trust and consistency for patients, and provide a real pathway to effective, standardized treatments,” said Julie Armstrong, CEO of Aurelius Data, Inc. #AureliusData

“The Moonshot is to let the data lead the way to identifying novel approaches to treatment, new therapies and outcomes; All without the bias of marketing and advertising, and without the influence of sources who don’t have the patient’s best outcomes as a focus. We recognize our responsibility to the subscribership of ASA and seek to honor this collaboration through providing fresh insights and a value-added community through our AURA platform”, said Armstrong.  #BeyondTheStrain

“In that spirit, we’re very enthusiastic about the potential of this groundbreaking partnership to drive solutions and improve outcomes for cannabis patients and consumers everywhere,” said Churgai.

Americans for Safe Access
The mission of Americans for Safe Access (ASA) is to ensure safe and legal access to cannabis (marijuana) for therapeutic use and research.

ASA was founded in 2002 as a vehicle for patients to advocate for the acceptance of cannabis as medicine. With over 100,000 advocates in all 50 states, ASA is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political, social and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, research, grassroots empowerment, advocacy and services for patients, governments, medical professionals, and medical cannabis providers.

Aurelius Data, Inc
Aurelius Data, Inc. (AD) is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution.
Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user.  Our anonymously gathered data follows HIPPA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the Strain and create a reliable product use and efficacy reference for cannabis users.